OBIMF (Ondine Biomedical) Tariff Resilience Score: 0/10 (As of Jul. 12, 2026)


OBIMF Ondine Biomedical Inc OBIMF
15 GF Score
Price $0.25
GF Value $0.20
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Ondine Biomedical Tariff Resilience Score?

Ondine Biomedical has the Tariff Resilience Score of 0, which implies that the company might have .

Ondine Biomedical has Ondine Biomedical, in the healthcare sector, faces moderate tariff risks. While medical products can be tariff-sensitive, the company may benefit from industry-specific exemptions and alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ondine Biomedical might have .

Ondine Biomedical  (OTCPK:OBIMF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ondine Biomedical Tariff Resilience Score Related Terms

OBIMF
15GF Score
Ondine Biomedical Inc OBIMF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ondine Biomedical (OBIMF) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of $0.25 is trading 25% above its estimated GF Value™ of $0.20. GuruFocus considers Ondine Biomedical to be Modestly Overvalued.

Key valuation signals for OBIMF:

  • Tariff Resilience Score: 0
  • GF Value™: $0.20 vs. price of $0.25 (25% above fair value)
  • GF Score™: 15/100 with 9 warning signs

No single metric tells the full story. See the OBIMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ondine Biomedical Business Description

Other Exchanges OBI:UKVF5:Germany
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
15GF Score

Get the complete analysis for OBIMF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.20
GF Value